Rezolute (RZLT) Liabilities and Shareholders Equity (2011 - 2026)

Rezolute recorded quarterly Liabilities and Shareholders Equity of $125.5 million in Q1 2026, down 9.5% quarter-over-quarter from $138.6 million in Q4 2025, and up 32.43% year-over-year from $94.7 million in Q1 2025.

Rezolute's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $125.5 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 32.43% year-over-year to $125.5 million; the TTM figure through Mar 2026 stood at $598.2 million (up 29.24% YoY), while the FY2025 annual figure was $175.5 million, up 32.21% from the prior year.
  • Liabilities and Shareholders Equity came in at $125.5 million for Q1 2026 at Rezolute, down from $138.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $175.5 million in Q2 2025 to a low of $69.6 million in Q1 2022.
  • A 5-year average of $126.5 million and a median of $125.5 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity surged 302.45% in 2022 and sank 34.62% in 2024, its largest moves.
  • Rezolute's Liabilities and Shareholders Equity stood at $150.2 million in 2022, then tumbled by 31.99% to $102.1 million in 2023, then advanced by 9.65% to $112.0 million in 2024, then rose by 23.77% to $138.6 million in 2025, then slipped by 9.5% to $125.5 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $125.5 million, $138.6 million, and $158.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 14.93 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 37.37 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.73 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 78.88 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 33.89 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 26.48 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 23.64 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 40.87 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 5.13 Bn
10 Rezolute 374.41 Mn 374.41 Mn - 125.46 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 125.46 Mn
Dec 31, 2025 138.63 Mn
Sep 30, 2025 158.66 Mn
Jun 30, 2025 175.49 Mn
Mar 31, 2025 94.74 Mn
Dec 31, 2024 112.01 Mn
Sep 30, 2024 123.41 Mn
Jun 30, 2024 132.74 Mn
Mar 31, 2024 87.74 Mn
Dec 31, 2023 102.15 Mn
Sep 30, 2023 113.00 Mn
Jun 30, 2023 123.72 Mn
Mar 31, 2023 134.21 Mn
Dec 31, 2022 150.21 Mn
Sep 30, 2022 155.99 Mn
Jun 30, 2022 152.42 Mn
Mar 31, 2022 69.57 Mn
Dec 31, 2021 83.41 Mn
Sep 30, 2021 38.76 Mn
Jun 30, 2021 42.61 Mn
Mar 31, 2021 32.93 Mn
Dec 31, 2020 38.90 Mn
Sep 30, 2020 7.41 Mn
Jun 30, 2020 10.97 Mn
Mar 31, 2020 14.70 Mn
Dec 31, 2019 20.57 Mn
Sep 30, 2019 26.57 Mn
Jun 30, 2019 12.25 Mn
Mar 31, 2019 15.46 Mn
Dec 31, 2018 455,662.00
Sep 30, 2018 1.07 Mn
Jun 30, 2018 2.50 Mn
Mar 31, 2018 5.14 Mn
Dec 31, 2017 6.32 Mn
Sep 30, 2017 9.80 Mn
Jun 30, 2017 10.63 Mn
Mar 31, 2017 10.80 Mn
Dec 31, 2016 9.94 Mn
Sep 30, 2016 10.06 Mn
Jun 30, 2016 10.90 Mn
Mar 31, 2016 8.79 Mn
Dec 31, 2015 8.53 Mn
Sep 30, 2015 9.17 Mn
Jun 30, 2015 11.26 Mn
Mar 31, 2015 12.06 Mn
Dec 31, 2014 10.72 Mn
Sep 30, 2014 6.27 Mn
Jun 30, 2014 7.40 Mn
Mar 31, 2014 6.27 Mn
Dec 31, 2013 2.15 Mn
Sep 30, 2013 863,570.00
Jun 30, 2013 1.10 Mn
Mar 31, 2013 1.57 Mn
Sep 30, 2012 480.00
Jun 30, 2012 1.07 Mn
Mar 31, 2012 8,888.00
Dec 31, 2011 565,789.00
Sep 30, 2011 23,478.00
Jun 30, 2011 37,030.00